TY  - BOOK
AU  - Garcia-Garcia, Hector M
TI  - Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention
SN  - 1936-8798
PY  - 2019///
KW  - *Angina, Stable/th [Therapy]
KW  - *Creatine Kinase, MB Form/bl [Blood]
KW  - *Percutaneous Coronary Intervention/mo [Mortality]
KW  - *Troponin T/bl [Blood]
KW  - Aged
KW  - Angina, Stable/bl [Blood]
KW  - Angina, Stable/di [Diagnosis]
KW  - Angina, Stable/mo [Mortality]
KW  - Biomarkers/bl [Blood]
KW  - Drug-Eluting Stents
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Percutaneous Coronary Intervention/ae [Adverse Effects]
KW  - Percutaneous Coronary Intervention/is [Instrumentation]
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - Up-Regulation
KW  - MedStar Heart & Vascular Institute
KW  - Journal Article
N1  - Available online through MWHC library: 2008 - present
N2  - BACKGROUND: Several studies have shown a strong association between post-PCI CK-MB elevation and subsequent mortality. However, the prognostic significance of troponin elevation following coronary intervention is still debated; CONCLUSIONS: Following elective PCI in patients in stable condition treated with second-generation drug-eluting stent, CK-MB and cTn elevations remain common. After multivariate adjustment, there was an increased mortality rate with elevation of CK-MB after PCI, whereas cTn elevation was not independently associated with mortality at 1 year. Copyright (c) 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved; METHODS: Patient-level data from 5 contemporary coronary stent trials and 1 large registry were pooled. Mortality of patients with stable angina, with normal baseline biomarkers, was compared between patients with and those without different cutoff values of cTn and CK-MB; OBJECTIVES: This study sought to explore the association between biomarker elevation, with creatine kinase-myocardial band (CK-MB) or cardiac troponin (cTn), following percutaneous coronary intervention (PCI) and mortality in patients undergoing PCI for stable angina with normal baseline values; RESULTS: A total of 13,452 patients were included in this pooled analysis. The overall percentage of patients with elevated biomarkers following PCI was 23.9% for CK-MB and 68.4% for cTn. In the patient cohort for whom both assays were available (n = 8,859), 2.4% had both CK-MB >=5 x the upper limit of normal (ULN) and cTn >=35 x ULN, while 92% had both CK-MB <5 x ULN and cTn <35 x ULN. Among patients with CK-MB >=5 x ULN (n = 315), 212 (67.3%) also had cTn >=35 x ULN. Conversely, 390 of patients (64.8%) who had cTn >=35 x ULN did not have CK-MB >=5 x ULN. A total of 259 patients (1.9%) died at 1 year; 20 (7.7%) had CK-MB >=5 x ULN, and 23 (8.8%) had cTn >=35 x ULN. In the Cox multivariate analysis, in which the CK-MB and cTn ratios post-procedure were forced into the model, age, prior myocardial infarction, lesion complexity, hyperlipidemia, and CK-MB ratio (>=10) post-procedure were associated with increased 1-year mortality
UR  - https://dx.doi.org/10.1016/j.jcin.2019.07.014
ER  -